Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Angiodynamics Inc (NQ: ANGO )

5.865 +0.075 (+1.30%)
Streaming Delayed Price Updated: 12:31 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Angiodynamics Inc

< Previous 1 2 Next >
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Completes Enrollment for PRESERVE Clinical Study
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the Needham Virtual Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Participate in Three Investor Conferences in March
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Present at the Piper Sandler Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance
From AngioDynamics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.